Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD\*

(a joint stock limited company established in the People's Republic of China with limited liability)

## (Stock Code: 8058)

## ANNOUNCEMENT

Reference is made to the annual results announcement for the year ended 31 December 2015 dated 21 March 2016 (the "**Results Announcement**"), the circular dated 6 May 2016, the notice of the 2015 annual general meeting (the "**AGM**") dated 6 May 2016, the poll results announcement dated 22 June 2016 and clarification announcement dated 27 June 2016 of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (the "**Company**").

The board of the directors of the Company (the "**Board**") would like to announce that the proposal for the payment of a final dividend of RMB0.35 per share (subject to applicable tax) for the year ended 31 December 2015 (the "**Final Dividend**") as recommended by the Board was approved by the shareholders of the Company at the AGM held on 22 June 2016.

According to the Articles of Association of the Company, dividends for holders of H Shares of the Company will be declared in RMB but paid in Hong Kong dollars (HK\$). The relevant conversion rate is calculated on the average price of the conversion of RMB into relevant foreign currencies as announced by the People's Bank of China in the five working days (i.e. 15 June 2016 to 21 June 2016) immediately prior to the AGM i.e. 22 June 2016. The average price of HK\$ against RMB over a period of five working days preceding the 22 June 2016 is HK\$1.00: RMB0.84767. Based on this exchange rate, the Final Dividend for every H Share is HK\$0.41290 (subject to applicable tax). Information relating to the application tax in respect of the Final Dividend can be found on pages 31 to 33 of the Results Announcement.

The Company has appointed Bank of China (Hong Kong) Trustee Limited as the receiving agent in Hong Kong (the "**Receiving Agent**") and will pay to the Receiving Agent the Final Dividend declared for payment to holders of H Shares. It is expected that the Final Dividend will be distributed by the Receiving Agent on or about 10 August 2016 to the holders of H Shares whose names appear on the register of members for H Shares of the Company after the close of business on 27 June 2016 (the "**Record Date**"). Should there be any changes to

\* For identification purpose only

expected payment date, the Company will make further announcement hereon. Relevant cheques will be dispatched to holders of H Shares entitled to receive the Final Dividend by ordinary post at their own risk.

## By order of the Board Shandong Luoxin Pharmaceutical Group Stock Co., Ltd\* Liu Baoqi Chairman

PRC, 20 July 2016

As at the date of this announcement, the Board comprises 10 Directors, of which Mr. Liu Baoqi (劉保起), Ms. Li Minghua (李明華), Mr. Han Fengsheng (韓風生), Mr. Chen Yu (陳雨) and Mr. Liu Zhenteng (劉振騰) are executive Directors; Mr. Liu Zhenhai (劉振海) is a non-executive Director; Mr. Foo Tin Chung, Victor (傅天忠), Mr. Fu Hongzheng (付宏征), Prof. Du Guanhua (杜冠華) and Ms. Huang Huiwen (黃慧文) are independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company's designated website at: http://shandongluoxin.quamir.com.

\* English names are translated for identification purposes only